EAN 2021 | Proof of concept trial: fecal microbiome transplantation in Parkinson’s disease

Filip Scheperjans, MD, PhD, Helsinki University Central Hospital, Helsinki, Finland, shares the details of an upcoming proof of concept trial (NCT04854291) of fecal microbiome transplantation (FMT) in patients with Parkinson’s disease (PD). The double-blind study will recruit 48 patients who have tested positive for stool PD-dysbiosis and randomize them 2:1 to receive donor FMT or their own stool via intracaecal infusion. The primary outcome measure will be the sum of MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) I-III, in order to capture the impact of FMT on both motor and non-motor symptoms. Several secondary outcome measures will also be assessed and biospecimens and imaging data will be collected for analysis over a 12-month period. This interview took place during the European Academy of Neurology 2021 congress.